In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Prelude Therapeutics Inc (NASDAQ: PRLD) was $0.79 for the day, down -8.69% from the previous closing price of $0.86. In other words, the price has decreased by -$8.69 from its previous closing price. On the day, 1.85 million shares were traded. PRLD stock price reached its highest trading level at $0.86 during the session, while it also had its lowest trading level at $0.77.
Ratios:
Our analysis of PRLD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.18. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On June 20, 2024, Barclays Downgraded its rating to Underweight which previously was Equal Weight but kept the price unchanged to $3.
On March 13, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 13, 2024, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 25 ’25 when Combs Andrew bought 100,000 shares for $0.69 per share. The transaction valued at 69,250 led to the insider holds 480,123 shares of the business.
Vaddi Krishna bought 675,000 shares of PRLD for $467,438 on Mar 25 ’25. The CEO now owns 1,999,296 shares after completing the transaction at $0.69 per share. On Mar 21 ’25, another insider, Vaddi Krishna, who serves as the CEO of the company, bought 15,000 shares for $0.73 each. As a result, the insider paid 10,959 and bolstered with 1,324,296 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRLD now has a Market Capitalization of 44338432 and an Enterprise Value of -36815584. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.33 while its Price-to-Book (P/B) ratio in mrq is 0.43. Its current Enterprise Value per Revenue stands at -5.259 whereas that against EBITDA is 0.266.
Stock Price History:
The Beta on a monthly basis for PRLD is 1.23, which has changed by -0.7917772 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, PRLD has reached a high of $6.80, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -13.15%, while the 200-Day Moving Average is calculated to be -33.83%.
Shares Statistics:
PRLD traded an average of 177.90K shares per day over the past three months and 279070 shares per day over the past ten days. A total of 43.60M shares are outstanding, with a floating share count of 24.35M. Insiders hold about 56.88% of the company’s shares, while institutions hold 34.41% stake in the company. Shares short for PRLD as of 1749772800 were 841037 with a Short Ratio of 4.73, compared to 1747267200 on 877740. Therefore, it implies a Short% of Shares Outstanding of 841037 and a Short% of Float of 11.399999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
